A transplant is often preferable to dialysis. While dialysis is a life-saving measure, it’s a lifetime commitment, and it has potential risks and complications. Your doctor determines whether you’re ...

Credit: Apellis. Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE)-- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that Health Canada has approved EMPAVELI ® (pegcetacoplan), a complement ...

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI ® (pegcetacoplan) as the ...

C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare and progressive kidney diseases, caused by problems in the immune system. They are two distinct ...

Pegcetacoplan (Empaveli) reduced proteinuria and helped stabilize kidney function in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (MPGN). The C3 and C3b ...

The FDA has approved pegcetacoplan (Empaveli, Apellis Pharmaceuticals, Inc.) for the treatment of C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...

Pegcetacoplan treatment led to proteinuria reduction and eGFR stabilization across important subgroups with C3 glomerulopathy and IC-MPGN. Pegcetacoplan induces a clinically meaningful ...

Apellis and Sobi's Aspaveli application for C3G and IC-MPGN treatment validated by the EMA, addressing rare kidney diseases. Apellis Pharmaceuticals and Sobi announced that the European Medicines ...

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) supplemental New Drug Application (sNDA) for ...

80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline 40% of patients showed zero staining intensity, indicating ...

EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in CanadaApproval supported ...